BIBF 1120 in Recurrent Glioblastoma Multiforme

Status Completed

Clinical Trial Summary

VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.

VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01251484
Study type	Interventional
Source	Rigshospitalet, Denmark
Contact
Status	Completed
Phase	Phase 2
Start date	January 2011
Completion date	August 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05577091` - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT05284643` - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A
Recruiting	`NCT05039281` - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04988750` - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients	N/A
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT00503204` - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour	Phase 1
Completed	`NCT03216499` - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma	Phase 2
Not yet recruiting	`NCT04717999` - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma	N/A
Not yet recruiting	`NCT05540275` - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Phase 2
Recruiting	`NCT04528680` - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma	Phase 1/Phase 2
Completed	`NCT04044937` - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms	Phase 2
Recruiting	`NCT04888611` - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma	Phase 2
Completed	`NCT00390299` - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1
Recruiting	`NCT05463848` - Surgical Pembro +/- Olaparib w TMZ for rGBM	Phase 2
Active, not recruiting	`NCT04479241` - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma	Phase 2
Active, not recruiting	`NCT00777153` - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma	Phase 3
Withdrawn	`NCT05017610` - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma	Early Phase 1
Recruiting	`NCT04323046` - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Phase 1
Active, not recruiting	`NCT05324501` - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma	Phase 1
Withdrawn	`NCT05666349` - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	Phase 1